Article
Oncology
Zining Wang, Feifei Xu, Jie Hu, Hongxia Zhang, Lei Cui, Wenhua Lu, Wenzhuo He, Xiaojuan Wang, Mengyun Li, Huanling Zhang, Wenjing Xiong, Chunyuan Xie, Yongxiang Liu, Penghui Zhou, Jinyun Liu, Peng Huang, Xiaofeng Frank Qin, Xiaojun Xia
Summary: Clotrimazole was identified as a drug that could enhance DC-mediated antigen presentation and T cell response, by acting on hexokinase 2 to regulate metabolic production and enhancing the lysosome pathway and Chop expression in DCs. In vivo administration of clotrimazole induced immune infiltration and inhibited tumor growth, synergizing with anti-PD1 antibody therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Xiaowu Bai, Chi Chun Wong, Yasi Pan, Huarong Chen, Weixin Liu, Jianning Zhai, Wei Kang, Yu Shi, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Philip Chiu, Jun Yu, Enders Kwok-wai Ng
Summary: YTHDF1 is overexpressed in gastric cancer and promotes cancer growth by inducing cell proliferation and suppressing dendritic cell-mediated anti-tumor immune response. YTHDF1 is a promising therapeutic target for gastric cancer treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Sara Nava, Daniela Lisini, Simona Frigerio, Anna Bersano
Summary: DCs vaccines have established safety and the ability to induce anti-tumor responses, and combining with other treatments may improve efficacy. Combinatorial approaches of DCs-based immunotherapy with chemotherapy and radiotherapy could be the key to cancer treatment paradigms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Razan Alzeibak, Tatiana A. Mishchenko, Natalia Y. Shilyagina, Irina V. Balalaeva, Maria V. Vedunova, Dmitri V. Krysko
Summary: The past decade has seen significant breakthroughs in cancer immunotherapy, with immunogenic cell death (ICD) emerging as a promising approach to eliminate tumor cells. Photodynamic therapy (PDT) can induce ICD, but its efficiency is reduced in hypoxic tumor environments. Future research may focus on strategies like oxygen-boosted PDT and nanotechnology to address this limitation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Katerina Kalkusova, Sindija Smite, Elea Darras, Pavla Taborska, Dmitry Stakheev, Luca Vannucci, Jirina Bartunkova, Daniel Smrz
Summary: The immune checkpoint inhibitors are crucial in cancer immunotherapy, but their efficacy is limited in solid tumors. Mast cells and dendritic cells play important roles in the tumor immune microenvironment and controlling these cells may help overcome the resistance of solid tumors to immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Engineering, Biomedical
Ying-Hua Guan, Na Wang, Zhen-Wei Deng, Xi-Guang Chen, Ya Liu
Summary: Dendritic cells (DCs) play a critical role in regulating immune response and anti-tumor process. However, immunosuppressive cells and factors in the tumor microenvironment pose challenges to DC function. Therefore, designing nanomaterials to regulate DC autophagy is important for enhancing immune function.
Article
Oncology
Giovanni Fuca, Margherita Ambrosini, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Serenella M. Pupa, Michele Magni, Liliana Devizzi, Paola Matteucci, Antonello Cabras, Roberta Zappasodi, Francesca De Santis, Andrea Anichini, Filippo De Braud, Alessandro M. Gianni, Massimo Di Nicola
Summary: This study provides a 15-year follow-up of vaccination with tumor-loaded DCs in relapsed iNHL patients, showing long-term benefit without significant toxicity, improved survival rates, and potential for long-lasting complete responses. Biomarker analysis revealed different gene expressions in responder versus non-responder tumors, indicating a potential for personalized treatment approaches. The study suggests that active immunization with DCs may be a promising strategy in relapsed iNHL treatment, warranting further investigation in combination with other novel immunotherapy agents.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Caiyun Liu, Jie Zhu, Yan Mi, Tao Jin
Summary: Dendritic cells (DCs) play a crucial role in autoimmune diseases such as multiple sclerosis (MS) and can be significantly affected by current disease-modifying therapies (DMT). The induction of tolerogenic DCs (tolDCs) has shown therapeutic potential in laboratory models and early clinical trials. Targeting specific cell-surface receptors to induce tolDCs in vivo has greater promise and advantages compared to in vitro induction.
JOURNAL OF NEUROINFLAMMATION
(2022)
Article
Oncology
Anastasia Prokopi, Christoph H. Tripp, Bart Tummers, Florian Hornsteiner, Sarah Spoeck, Jeremy Chase Crawford, Derek R. Clements, Mirjana Efremova, Katharina Hutter, Lydia Bellmann, Giuseppe Cappellano, Bruno L. Cadilha, Sebastian Kobold, Louis Boon, Daniela Ortner, Zlatko Trajanoski, Suzie Chen, Tanja D. de Gruijl, Juliana Idoyaga, Douglas R. Green, Patrizia Stoitzner
Summary: Immunotherapy with checkpoint inhibitors has shown impressive results in patients with melanoma, but many still do not benefit from this treatment due to factors such as lack of tumor-infiltrating T cells and loss of intratumoral dendritic cells. In a melanoma mouse model, researchers found that tumor progression is characterized by upregulation of checkpoint molecules and gradual loss of dermal conventional DC 2 subset. Monotherapy with checkpoint blockade was not effective, but boosting DC numbers and activation increased tumor immunogenicity, leading to improved T cell function and delayed tumor growth when combined with antibodies against PD-1 and TIM-3. The study highlights the importance of skin DC in cancer immunotherapy and suggests that restoring DC function is key to enhancing tumor immunogenicity and responsiveness to checkpoint blockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cell Biology
Md Masud Alam, De Yang, Xiao-Qing Li, Jia Liu, Timothy Carrel Back, Anna Trivett, Baktiar Karim, Denise Barbut, Michael Zasloff, Joost J. Oppenheim
Summary: Recent studies have shown that alpha-synuclein plays a crucial role in normal vertebrate physiology and is a critical mediator of inflammatory and immune responses. Neural cells are the sources of alpha-synuclein required for immune competence.
Article
Oncology
Bhuwan Giri, Prateek Sharma, Tejeshwar Jain, Anthony Ferrantella, Utpreksha Vaish, Siddharth Mehra, Bharti Garg, Srikanth Iyer, Vrishketan Sethi, Zoe Malchiodi, Rossana Signorelli, Harrys K. C. Jacob, John George, Preeti Sahay, Ejas P. Bava, Rajinder Dawra, Sundaram Ramakrishnan, Ashok Saluja, Vikas Dudeja
Summary: The absence of Hsp70 in the tumor microenvironment inhibits tumor growth through immune cells, and Hsp70(-/-) dendritic cells inhibit tumor growth by enhancing the immune response.
Article
Oncology
Hemavathi Dhandapani, Hascitha Jayakumar, Abirami Seetharaman, Shirley Sunder Singh, Selvaluxmy Ganeshrajah, Nirmala Jagadish, Anil Suri, Rajkumar Thangarajan, Priya Ramanathan
Summary: Dendritic cell-based immunotherapy utilizing recombinant human SPAG9 shows promise in stimulating CD4(+) and CD8(+) T cell responses for cervical cancer patients. The study suggests rhSPAG9 as a strong immunogen for DC-based immunotherapy and highlights the potential of a combinatorial regimen with cisplatin for therapeutic intervention.
CANCER CELL INTERNATIONAL
(2021)
Review
Immunology
Ya-Jui Lin, Caren Yu-Ju Wu, Janet Yuling Wu, Michael Lim
Summary: Glioblastoma is a highly aggressive glioma with resistance to immunotherapy, primarily due to the unique immune environment. Myeloid cells play a significant role in the glioma microenvironment and reprogramming them has emerged as a revolutionary immunotherapy for glioma treatment. This article provides a detailed classification and analysis of myeloid cells in glioma TME, aiming to offer new insights and therapeutic approaches for improving treatment efficacy in glioma patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yue Liu, Joanna Pagacz, Donald J. Wolfgeher, Kenneth D. Bromerg, Jacob Gorman, Stephen J. Kron
Summary: Antigen presentation may be the limiting factor in the low immune response to radiation therapy, and combining immune checkpoint blockade does not restore cytotoxic T lymphocytes function. Therapeutic vaccines based on senescent tumor cells or SnC-activated dendritic cells have the potential to enhance immune therapies and limit recurrence or metastasis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Tomoko Ito, Kikuya Sugiura, Aya Hasegawa, Wakana Ouchi, Takayuki Yoshimoto, Izuru Mizoguchi, Toshio Inaba, Katsuyuki Hamada, Masazumi Eriguchi, Yoshiyuki Koyama
Summary: Treatment with tumor-derived EVs showed limited antitumor effect on established tumors due to their immuno-suppressive functions and the poor immunogenicity of TAAs. By genetically modifying parent tumor cells to express a highly immunogenic bacterial antigen, ESAT-6, the EVs exhibited significantly improved antitumor activity in tumor-bearing mice.
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.